Ultrasound Radiomics-Based Machine Learning and SHapley Additive exPlanations Method Predicting Pathological Prognostic Stage in Breast Cancer: A Bicentric and Validation Study
Clinical Breast Cancer · 2025
DOI: 10.1016/j.clbc.2025.05.001 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Lei Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, Fujian Medical University Affiliated Union Hospital, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Machine Learning, Ultrasonography, Mammary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To build and validate ultrasound (US) radiomics-based machine learning (ML) models to predict the pathological prognostic stage of breast cancer (BCa). METHODS: We retrospectively included 578 BCa patients from two hospitals (468 and 110 in the training and test sets, respectively). For each patient, the pathological prognostic stage was determined. US radiomics features were extracted, preprocessed, and selected. Five US radiomics-based ML models were built to distinguish between pathological prognostic stage II-III and 0-I groups. The fusion model was built by combining the optimal radiomics model with clinical indicators. Receiver operating characteristic (ROC) curve analysis was applied to evaluate the performance of the models. SHapley Additive exPlanations (SHAP) method was used to interpret the models. RESULTS: For each lesion, 1333 US radiomics features were extracted and 11 features were finally selected to build models. The MLP model achieved optimal performance with the AUC of 0.893 and 0.806 in the training and test sets, respectively. The AUC of the fusion model was 0.913 and 0.823 in training and test sets, respectively. The squareroot_glszm_GrayLevelNonUniformity and wavelet-LHH_gldm_DependenceVariance were the most important features of the MLP model and fusion model, respectively. CONCLUSIONS: US radiomics-based ML is helpful for preoperatively predicting the pathological prognostic stage of BCa, which has potential reference value for making individualized treatment strategies and predicting disease prognosis in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ultrasound, Fujian Medical University Affiliated Union Hospital, Fuzhou, Fujian, China.
- Department of Ultrasound, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China.
- Department of Ultrasound, Fujian Maternity and Child Health Hospital, Fuzhou, Fujian, China.
- Department of Ultrasound, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
- Department of Ultrasound, Fujian Medical University Affiliated Union Hospital, Fuzhou, Fujian, China. Electronic address: jimchen2003@163.com.
Zitieren
APA
Chen, L., Su, Y., Wang, Y., Yu, Y., Huang, D., Zhang, M., Chen, X., Ye, X., He, Y., Xue, E., Lin, L., & Chen, Z. (2025). Ultrasound Radiomics-Based Machine Learning and SHapley Additive exPlanations Method Predicting Pathological Prognostic Stage in Breast Cancer: A Bicentric and Validation Study. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.05.001
Vancouver
Chen L, Su Y, Wang Y, Yu Y, Huang D, Zhang M, et al. Ultrasound Radiomics-Based Machine Learning and SHapley Additive exPlanations Method Predicting Pathological Prognostic Stage in Breast Cancer: A Bicentric and Validation Study. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.05.001
BibTeX
@article{Chen2025,
author = {Chen, Lei and Su, YiXi and Wang, Yaoqin and Yu, Yue and Huang, Danfeng and Zhang, Meilian and Chen, Xiaoshuang and Ye, Xu and He, Yimi and Xue, Ensheng and Lin, Liwu and Chen, Zhikui},
title = {Ultrasound Radiomics-Based Machine Learning and SHapley Additive exPlanations Method Predicting Pathological Prognostic Stage in Breast Cancer: A Bicentric and Validation Study},
journal = {Clinical Breast Cancer},
year = {2025},
doi = {10.1016/j.clbc.2025.05.001}
}
EUVIMED